Dose-Ranging Safety and Immunogenicity Study of Live Attenuated Varicella-Zoster Virus Vaccine (Oka/Merck) Administered to Adults 60 Years of Age or Older.

Abstract
No abstract available

This publication has 0 references indexed in Scilit: